Search

Your search keyword '"Hansen, Jakob W."' showing total 4 results
Start Over Author "Hansen, Jakob W." Journal blood
4 results on '"Hansen, Jakob W."'

1. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Author

Eskelund, Christian W., Dahl, Christina, Hansen, Jakob W., Westman, Maj, Kolstad, Arne, Pedersen, Lone B., Montano-Almendras, Carmen P., Husby, Simon, Freiburghaus, Catja, Ek, Sara, Pedersen, Anja, Niemann, Carsten, Räty, Riikka, Brown, Peter, Geisler, Christian H., Andersen, Mette K., Guldberg, Per, Jerkeman, Mats, and Grønbæk, Kirsten

Published
2017
Full Text
View/download PDF

2. An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma

Author

El-Galaly, Tarec Christoffer, primary, Cheah, Chan Yoon, additional, Bendtsen, Mette Dahl, additional, Thanarasjasingam, Gita, additional, Kansara, Roopesh, additional, Savage, Kerry J, additional, Connors, Joseph M., additional, Goldschmidt, Neta, additional, Shaulov, Adir, additional, Farooq, Umar, additional, Sehn, Laurie H, additional, Dann, Eldad J, additional, Thompson, Carrie A, additional, Inbar, Tsofia, additional, Link, Brian K, additional, Maurer, Matthew J, additional, Gade, Inger Lise, additional, Juul, Maja Bech, additional, Hansen, Jakob W, additional, Holmberg, Staffan, additional, Larsen, Thomas S, additional, Opat, Stephen, additional, Mikhaeel, N George, additional, Seymour, John F, additional, Clausen, Michael Roost, additional, Smith, Daniel, additional, Gilbertson, Michael, additional, Nowakowski, Grzegorz S, additional, Cordua, Sabrina, additional, Hutchings, Martin, additional, and Villa, Diego, additional

Published
2016
Full Text
View/download PDF

3. Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Author

Eskelund, Christian Winther, primary, Hansen, Jakob W, additional, Westman, Maj Karoline, additional, Freiburghaus, Catja, additional, Ek, Sara, additional, Pedersen, Lone B, additional, Andersen, Mette K, additional, Räty, Riikka, additional, Kolstad, Arne, additional, Jerkeman, Mats, additional, Brown, Peter de Nully, additional, Geisler, Christian H, additional, and Groenbaek, Kirsten, additional

Published
2016
Full Text
View/download PDF

4. TP53mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Author

Eskelund, Christian W., Dahl, Christina, Hansen, Jakob W., Westman, Maj, Kolstad, Arne, Pedersen, Lone B., Montano-Almendras, Carmen P., Husby, Simon, Freiburghaus, Catja, Ek, Sara, Pedersen, Anja, Niemann, Carsten, Räty, Riikka, Brown, Peter, Geisler, Christian H., Andersen, Mette K., Guldberg, Per, Jerkeman, Mats, and Grønbæk, Kirsten

Abstract

Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are still unable to identify patients who will not benefit from the current standard of care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger patients with MCL from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53(11%) and NOTCH1(4%), and deletions of TP53(16%) and CDKN2A(20%), were significantly associated with inferior outcomes (together with MIPI, MIPI-c, blastoid morphology, and Ki67 > 30%); however, in multivariate analyses, only TP53mutations (HR, 6.2; P< .0001) retained prognostic impact for overall survival (OS), whereas TP53mutations (HR, 6.9; P< .0001) and MIPI-c high-risk (HR, 2.6; P= .003) had independent prognostic impact on time to relapse. TP53-mutated cases had a dismal outcome, with a median OS of 1.8 years, and 50% relapsed at 1.0 years, compared to a median OS of 12.7 years for TP53-unmutated cases (P< .0001). TP53mutations were significantly associated with Ki67 > 30%, blastoid morphology, MIPI high-risk, and inferior responses to both induction- and high-dose chemotherapy. In conclusion, we show that TP53mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to regimens including cytarabine, rituximab, and autologous stem-cell transplant (ASCT). We suggest patients with MCL should be stratified according to TP53status, and that patients with TP53mutations should be considered for experimental frontline trials exploring novel agents.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results